Patents by Inventor Dawn PHILLIPS

Dawn PHILLIPS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230201318
    Abstract: The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., a child or an adolescent having HPP) exhibiting gait impairments or decreased walking ability by administering a soluble alkaline phosphatase (sALP) to the patient and assessing improvement in the gait impairment using a modified Performance-Oriented Mobility Assessment—Gait (mPOMA-G) analysis and score.
    Type: Application
    Filed: November 21, 2022
    Publication date: June 29, 2023
    Inventors: Kenji FUJITA, Marc VALLEE, Dawn PHILLIPS
  • Publication number: 20200306350
    Abstract: The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., a child or an adolescent having HPP) exhibiting gait impairments or decreased walking ability by administering a soluble alkaline phosphatase (sALP) to the patient and assessing improvement in the gait impairment using a modified Performance-Oriented Mobility Assessment-Gait (mPOMA-G) analysis and score.
    Type: Application
    Filed: June 27, 2016
    Publication date: October 1, 2020
    Inventors: Kenji FUJITA, Marc VALLEE, Dawn PHILLIPS
  • Publication number: 20190099473
    Abstract: The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., a child having HPP) exhibiting physical impairments, disability in activities of daily living (ADL), pain, and/or delayed motor development by administering a soluble alkaline phosphatase (sALP) to the patient.
    Type: Application
    Filed: September 1, 2016
    Publication date: April 4, 2019
    Inventors: Kenji FUJITA, Dawn PHILLIPS
  • Publication number: 20190060419
    Abstract: The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., adolescent or adult having HPP) exhibiting physical impairments or decreased walking ability by administering a soluble alkaline phosphatase (sALP) to the patient.
    Type: Application
    Filed: March 31, 2017
    Publication date: February 28, 2019
    Inventors: Kenji FUJITA, Dawn PHILLIPS, Agustin MELIAN